logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
L

Linda Mileshkin

Peter MacCallum Cancer Centre

72H-index
562Paper Count
3.3WCitation Count
Published Papers 140
Publication Date
logo
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
errBritish Journal of Cancer
IF6.8
err2026-07-08
err0
errOAAI
errKatrin M. Sjoquist; Alexander Dobrovic; Kristy P. Robledo; Ksenija Nesic; Sally Baron-Hay; Sumitra Ananda; Nicole McCarthy; Jeffrey Goh; Christopher Steer; Nick Murray; Sonia Yip; Linda R. Mileshkin; J. Lynn Fink; Garry Chang; Lisa Bailey; Yvonne Lee; Danka S. Zebic; U. G. Imalki U. Kariyawasam; Kristy Shield-Artin; Andrew Jarratt; Justin Bedő; Anthony T. Papenfuss; Olga Kondrashova; Matthew J. Wakefield; Cassandra J. Vandenberg; Martin R. Stockler; Clare L. Scott; Paul M. Waring
errShare
errSave
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting
errInternational Journal of Gynecological Cancer
IF4.7
err2026-06-23
err0
errOAAI
errAinhoa Madariaga; Ana Veneziani; Michael Bookman; Nicholas Counsell; Austin Miller; John Andrews; Susana Banerjee; Adriana Chavez-Blanco; Noelle Cloven; Faiza Gaba; Elise Kohn; Alexandra Leary; Fabrice Lecuru; Yeh Chen Lee; Jung Yun Lee; Ying Liu; Kristina Lindemann; Shakuntala Malik; Christian Marth; Linda Mileshkin
errShare
errSave
Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223)
errGynecologic Oncology
IF4.1
err2026-04-23
err0
PREAI
errAlexander Olawaiye; Stanislas Quesada; Lucy Gilbert; Jae-Weon Kim; Mariana Scaranti; Elena Giudice; Elizabeth Hopp; Linda Mileshkin; Toon Van Gorp; Michael McCollum; Ana Oaknin; Aliza Leiser; Philippe Follana; Chiara Cassani; Boglárka Balázs; Andrew Clamp; Hristina Pashova; Sachin Pai; Nicoletta Colombo; Domenica Lorusso
errShare
errSave
The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations
errModern Pathology
IF5.5
err2026-04-10
err0
errOAAI
errMerve Kaya; Lawrence H. Lin; Jan Oosting; Melanie E. Powell; Emma J. Crosbie; Alexandra Leary; Linda R. Mileshkin; Lois Shepherd; Marco de Bruyn; Jan Jobsen; Judith R. Kroep; Carien L. Creutzberg; Nanda Horeweg; Alicia Léon-Castillo; Carlos Parra-Herran; Vincent T.H.B.M. Smit; Marisa R. Nucci; Tjalling Bosse
errShare
errSave
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
errThe Lancet
IF88.5
err2026-04-10
err0
errOAAI
errDomenica Lorusso; Laurence Gladieff; David M O'Malley; Jae-Weon Kim; Gabriel Garbaos; Anna Fagotti; Lucy Gilbert; Linda Mileshkin; Stanislas Quesada; Elizabeth Hopp; Yong Jae Lee; Ana Oaknin; Mariana Scaranti; Byoung-Gie Kim; Andrew Clamp; Christina Prillaman; Connie Diakos; Andrea Bagaméri; Aliza L Leiser; Vanda Salutari
errShare
errSave
Survival and Patterns of Failure in Small Cell Neuroendocrine Carcinoma of the Cervix Treated with Definitive Chemoradiotherapy
errInternational Journal of Gynecological Cancer
IF4.7
err2025-12-15
err0
errOAAI
errJulianne O’Shea; Kelvin Yu; David Chang; Pearly Khaw; Linda Mileshkin; Orla McNally; Kailash Narayan; Srinivas Kondalsamy-Chennakesavan; Ming Yin Lin
errShare
errSave
Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies
errJournal of Geriatric Oncology
IF2.7
err2025-09-29
err0
errOAAI
errAdel Shahnam; Nadia Hitchen; Sathya Manoharan; Thomas John; Linda Mileshkin; Benjamin Solomon; Shahneen Sandhu; Stephen J. Luen; Jayesh Desai; Ben Tran
errShare
errSave
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
errlancet oncology
IF0
err2025-09-05
err0
errOAAI
errCathalijne C B Post; Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Alexandra Leary; Petronella B Ottevanger; Mary McCormack; Pearly Khaw; Romerai D'Amico; Anthony Fyles; Cyrus Chargari; Henry C Kitchener; Viet Do; Andrea Lissoni; Diane Provencher; Catherine Genestie; Hans W Nijman; Karen Whitmarsh; Ina M Jürgenliemk-Schulz; Amanda Feeney; Ludy C H W Lutgens; Jeanette Bouma; Alicia Leon-Castillo; Remi A Nout; Hein Putter; Tjalling Bosse; Carien L Creutzberg
errShare
errSave
Cancer of the corpus uteri: A 2025 update
errInternational Journal of Gynecology & Obstetrics
IF2.4
err2025-07-07
err0
PREAI
errMartin Koskas; Emma J. Crosbie; Lars Fokdal; W. Glenn McCluggage; Linda Mileshkin; David G. Mutch; Frédéric Amant
errShare
errSave
Erratum to ‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]
errInternational Journal of Gynecological Cancer
IF4.7
err2025-06-11
err0
PREAI
errAndreas Obermair; Val Gebski; Jeffrey Goh; Anna Kuchel; Alison Brand; Blossom Mak; Orla McNally; Eva Baxter; Thomas Jobling; Linda Mileshkin
errShare
errSave
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary
errNATURE COMMUNICATIONS
IF15.7
err2025-05-20
err0
errOAAI
errRebello, Richard J.; Posner, Atara; Dong, Ruining; Prall, Owen W. J.; Sivakumaran, Tharani; Mitchell, Camilla B.; Flynn, Aidan; Caneborg, Alex; Mitchell, Catherine; Kanwal, Sehrish; Fedele, Clare; Webb, Samantha; Fisher, Krista; Wong, Hui-Li; Balachander, Shiva; Zhu, Wenying; Nicolson, Shannon; Dimitriadis, Voula; Wilcken, Nicholas; Defazio, Anna; Gao, Bo; Singh, Madhu; Collins, Ian M.; Steer, Christopher; Warren, Mark; Karanth, Narayan; Xu, Huiling; Fellowes, Andrew; Hicks, Rodney J.; Stewart, Kym Pham; Shale, Charles; Priestley, Peter; Dawson, Sarah-Jane; Vissers, Joseph H. A.; Fox, Stephen B.; Schofield, Penelope; Bowtell, David; Hofmann, Oliver; Grimmond, Sean M.; Mileshkin, Linda; Tothill, Richard W.
errShare
errSave
Identifying H&E-based Immune Patterns in Endometrial Carcinoma and Their Association with Clinicopathologic Variables, Tumor Mutational Landscape, and Survival
errLABORATORY INVESTIGATION
IF4.2
err2025-03-01
err0
PREAI
errKaya, Merve; Lin, Lawrence; Powell, Melanie; Crosbie, Emma; Leary, Alexandra; Mileshkin, Linda; Shepherd, Lois; Bruyn, Marco; Creutzberg, Carien; Horeweg, Nanda; del Castillo, Alicia Leon; Parra-Herran, Carlos; Smit, Vincent; Nucci, Marisa; Bosse, Tjalling
errShare
errSave
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
errgynecologic oncology
IF4.1
err2025-02-01
err2
PREAI
errO'Malley, David M.; Bariani, Giovani M.; Cassier, Philippe A.; Marabelle, Aurelien; Hansen, Aaron R.; Acosta, Ana De Jesus; Miller Jr, Wilson H.; Safra, Tamar; Italiano, Antoine; Mileshkin, Linda; Yao, Lili; Gozma, Alexander; Jin, Fan; Maio, Michele
errShare
errSave
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin
errBMC CANCER
IF3.4
err2025-01-29
err0
errOAAI
errUgalde, Anna; Tothill, Richard W.; Quinn, Stephen; Wong, Hui-Li; Prall, Owen; Mitchell, Catherine; Wickramasinghe, Nilmini; Fedele, Clare; Richards, Natalie; Todio, Elizabeth; Bryant, Cindy; Collins, Louisa G.; Mclean, Sarah; Ko, Hyun Soo; Akhurst, Tim; Steer, Christopher; Gao, Bo; Wong, Mark; Georgiou, Chloe; Karanth, Narayan; Kuchel, Anna; Nott, Louise; Padinharakam, Shamsudheen; Shackleton, Mark; Collins, Ian M.; Singh, Madhu; Wong, Rachel; Wong, Zee Wan; Butler, Alexis; Sivakumaran, Tharani; Schofield, Penelope; Mileshkin, Linda
errShare
errSave
Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis
errJNCI CANCER SPECTRUM
IF4.1
err2024-10-21
err0
errOAAI
errTjokrowidjaja, Angelina; Kok, Peey-Sei; Antill, Yoland C.; Scott, Clare L.; Mileshkin, Linda R.; Friedlander, Michael L.; Lee, Chee K.
errShare
errSave
Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary
errJOURNAL OF NUCLEAR MEDICINE
IF9.1
err2024-09-05
err0
PREAI
errSivakumaran, Tharani; Cardin, Anthony; Callahan, Jason; Wong, Hui-li; Tothill, Richard W.; Hicks, Rodney J.; Mileshkin, Linda R.
errShare
errSave
ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errNicum, S.; Ledermann, J. A.; Mileshkin, L.; Jayson, G. C.; Gourley, C.; Michael, A.; Lord, R.; Mackay, H.; Hall, M.; Tookman, L.; Banerjee, S.; Harnett, P.; Macdonald, I.; Lee, Y. C.; Elyashiv, O.; Wilkinson, K.; Farrelly, L.; Counsell, N.
errShare
errSave
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errShapira-Frommer, R.; Sudo, K.; Harano, K.; Mileshkin, L.; Perets, R.; Song, M.; Cohen, J.; Huang, Y-F.; Ambrose, H.; Brier, T.; Dosani, A.; Fraenkel, P. G.; Kmieciak, A.; Mitchell, P.; Myers, C.; Wang, J.; Odegbami, R. I.; Sykes, A.; Turner, S.; Meric-Bernstam, F.
errShare
errSave
Outcomes of patients (pts) with unfavourable, nonsquamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errBochtler, T.; Kraemer, A.; Pauli, C.; Duran-Pacheco, G.; Arslan, C.; Bigot, F.; Chalabi, N.; Cook, N.; Italiano, A.; Losa, F.; Menezes, J.; Ma, N.; Ozguroglu, M.; Pazo Cid, R. A.; Ross, J. S.; Shiu, K-K.; Arni, P.; Moch, H.; Mileshkin, L.
errShare
errSave
Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err1
PREAI
errMeric-Bernstam, F.; Naito, Y.; Gaillard, S.; Shimoi, T.; Chung, V.; Davis, A. A.; Proia, T.; Ayyoub, A.; Kulkarni, M.; Upadhyay, S.; Miller, N.; Luheshi, N.; Varga, A.; Oh, D-Y.; Mileshkin, L.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
M
Mark J. Smyth
H-index: 172 · Papers: 1.4K
J
Jean‐Yves Blay
H-index: 158 · Papers: 2.4K
F
Fabrice André
H-index: 148 · Papers: 1.8K
F
Funda Meric‐Bernstam
H-index: 146 · Papers: 2.6K
I
Ingrid E. Scheffer
H-index: 141 · Papers: 1.0K
View more